JP Morgan Chase
CTMX icon

JP Morgan Chase’s CytomX Therapeutics CTMX Stock Holding History

JP Morgan Chase’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$409K Buy
109,413
+78,672
+256% +$300K ﹤0.01% 5226
2026
Q1 		$136K Buy
30,741
+6,378
+26% +$32.4K ﹤0.01% 5677
2025
Q4 		$104K Buy
24,363
+8,211
+51% +$31.2K ﹤0.01% 5869
2025
Q3 		$51.5K Buy
16,152
+15,871
+5,648% +$35.7K ﹤0.01% 6218
2025
Q2 		$638 Sell
281
-105,013
-100% -$169K ﹤0.01% 6671
2025
Q1 		$66.9K Sell
105,294
-706,336
-87% -$548K ﹤0.01% 5759
2024
Q4 		$836K Buy
811,630
+811,349
+288,736% +$873K ﹤0.01% 4753
2024
Q3 		$332 Hold
281
– – ﹤0.01% 6843
2024
Q2 		$343 Hold
281
– – ﹤0.01% 6728
2024
Q1 		$613 Hold
281
– – ﹤0.01% 6689
2023
Q4 		$436 Sell
281
-1,449
-84% -$1.91K ﹤0.01% 6944
2023
Q3 		$2.23K Hold
1,730
– – ﹤0.01% 6527
2023
Q2 		$2.98K Hold
1,730
– – ﹤0.01% 6279
2023
Q1 		$3K Hold
1,730
– – ﹤0.01% 6339
2022
Q4 		$3K Sell
1,730
-2,672
-61% -$3.95K ﹤0.01% 6240
2022
Q3 		$6K Buy
4,402
+1,425
+48% +$2.19K ﹤0.01% 6054
2022
Q2 		$5K Sell
2,977
-302,055
-99% -$578K ﹤0.01% 6153
2022
Q1 		$814K Sell
305,032
-2,197
-0.7% -$8.44K ﹤0.01% 4410
2021
Q4 		$1.33M Sell
307,229
-13,037
-4% -$76.4K ﹤0.01% 4174
2021
Q3 		$1.63M Sell
320,266
-21,269
-6% -$114K ﹤0.01% 3943
2021
Q2 		$2.16M Buy
341,535
+269,329
+373% +$2.1M ﹤0.01% 3742
2021
Q1 		$559K Sell
72,206
-8,318
-10% -$65.8K ﹤0.01% 4612
2020
Q4 		$528K Sell
80,524
-11,781
-13% -$84.2K ﹤0.01% 4334
2020
Q3 		$618K Sell
92,305
-7,275
-7% -$54K ﹤0.01% 3884
2020
Q2 		$828K Sell
99,580
-76,433
-43% -$710K ﹤0.01% 3616
2020
Q1 		$1.35M Sell
176,013
-192,992
-52% -$1.35M ﹤0.01% 3225
2019
Q4 		$3.07M Buy
369,005
+234,743
+175% +$1.58M ﹤0.01% 3072
2019
Q3 		$991K Buy
134,262
+6,969
+5% +$68.7K ﹤0.01% 3843
2019
Q2 		$1.35M Sell
127,293
-7,166
-5% -$75.1K ﹤0.01% 3663
2019
Q1 		$1.45M Sell
134,459
-8,611
-6% -$127K ﹤0.01% 3565
2018
Q4 		$2.16M Sell
143,070
-7,514
-5% -$111K ﹤0.01% 3226
2018
Q3 		$2.79M Buy
150,584
+10,653
+8% +$243K ﹤0.01% 3219
2018
Q2 		$3.2M Sell
139,931
-61,130
-30% -$1.56M ﹤0.01% 3037
2018
Q1 		$5.72M Sell
201,061
-42,478
-17% -$1.21M ﹤0.01% 2466
2017
Q4 		$5.14M Buy
243,539
+4,989
+2% +$103K ﹤0.01% 2656
2017
Q3 		$4.31M Sell
238,550
-4,200
-2% -$65.5K ﹤0.01% 2661
2017
Q2 		$3.76M Buy
242,750
+56,972
+31% +$859K ﹤0.01% 2669
2017
Q1 		$3.21M Buy
185,778
+157,261
+551% +$2.07M ﹤0.01% 2732
2016
Q4 		$313K Buy
+28,517
New +$346K ﹤0.01% 3976

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

JP Morgan Chase's CTMX Position: Q2 2026 in Review

JP Morgan Chase increased its CytomX Therapeutics (CTMX) stake by 256% in Q2 2026, buying an estimated $300K and bringing the position to 109,413 shares worth $409K. The position accounts for ﹤0.01% of the portfolio, ranked #5226.

JP Morgan Chase first reported a position in CTMX in Q4 2016 and has held it in 39 quarters since. The position peaked at $5.72M in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • JP Morgan Chase held 109,413 shares of CytomX Therapeutics worth $409K as of Q2 2026.
  • JP Morgan Chase bought 78,672 CytomX Therapeutics shares in Q2 2026, an estimated $300K.
  • CytomX Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5226 holding.
  • JP Morgan Chase first reported a position in CytomX Therapeutics in Q4 2016 and has held it in 39 quarters since.
  • JP Morgan Chase's CytomX Therapeutics position peaked at $5.72M in Q1 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.